Editas Medicine (EDIT) Depreciation & Amortization (CF) (2015 - 2025)
Editas Medicine (EDIT) posted quarterly Depreciation & Amortization (CF) of $721000.0 for Q3 2025, down 54.91% year-over-year from $1.6 million in Q3 2024, and down 60.69% quarter-over-quarter from $1.8 million in Q2 2025.
Editas Medicine (EDIT) Depreciation & Amortization (CF) (2015 - 2025) Analysis & Trends
Editas Medicine (EDIT) has reported Depreciation & Amortization (CF) for 11 consecutive years, with $721000.0 the latest figure, recorded in Q3 2025.
- In Q3 2025, Depreciation & Amortization (CF) fell 54.91% year-over-year to $721000.0; the TTM figure through Dec 2025 stood at $4.5 million (down 23.02% YoY), while the FY2024 annual figure was $5.8 million, down 4.77% from the prior year.
- Depreciation & Amortization (CF) declined to $721000.0 in Q3 2025 per EDIT's latest filing, from $1.8 million in the prior quarter.
- Across five years, Depreciation & Amortization (CF) topped out at $1.9 million in Q1 2025 and bottomed at $721000.0 in Q3 2025.
- Historically, Depreciation & Amortization (CF) has averaged $1.5 million across 5 years, with a median of $1.5 million in 2023.
- Annual changes were most pronounced in 2021 — Depreciation & Amortization (CF) jumped 45.74% — and 2025, when it plunged 54.91%.
- Editas Medicine's Depreciation & Amortization (CF) stood at $1.6 million in 2021, then rose by 1.22% to $1.6 million in 2022, then retreated by 4.76% to $1.5 million in 2023, then fell by 8.06% to $1.4 million in 2024, then sank by 47.79% to $721000.0 in 2025.
- Business Quant data shows EDIT's Depreciation & Amortization (CF) at $721000.0 in Q3 2025, $1.8 million in Q2 2025, and $1.9 million in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 56.50 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 123.70 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.10 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 40.52 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 3.18 Mn |
| 10 | Editas Medicine | 263.01 Mn | 116.36 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 721,000.00 |
| Sep 30, 2025 | 721,000.00 |
| Jun 30, 2025 | 1.83 Mn |
| Jun 30, 2025 | 1.83 Mn |
| Mar 31, 2025 | 1.92 Mn |
| Mar 31, 2025 | 1.92 Mn |
| Dec 31, 2024 | 1.38 Mn |
| Dec 31, 2024 | 1.38 Mn |
| Sep 30, 2024 | 1.60 Mn |
| Sep 30, 2024 | 1.60 Mn |
| Jun 30, 2024 | 1.42 Mn |
| Jun 30, 2024 | 1.42 Mn |
| Mar 31, 2024 | 1.41 Mn |
| Mar 31, 2024 | 1.41 Mn |
| Dec 31, 2023 | 1.50 Mn |
| Dec 31, 2023 | 1.50 Mn |
| Sep 30, 2023 | 1.51 Mn |
| Sep 30, 2023 | 1.51 Mn |
| Jun 30, 2023 | 1.54 Mn |
| Jun 30, 2023 | 1.54 Mn |